These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11422050)

  • 1. Intralesional rituximab for cutaneous B-cell lymphoma.
    Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
    Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody.
    Soda R; Costanzo A; Cantonetti M; Orlandi A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2001; 81(3):207-8. PubMed ID: 11558880
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
    Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
    Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
    Tobinai K; Kobayashi Y; Narabayashi M; Ogura M; Kagami Y; Morishima Y; Ohtsu T; Igarashi T; Sasaki Y; Kinoshita T; Murate T
    Ann Oncol; 1998 May; 9(5):527-34. PubMed ID: 9653494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
    Aboulafia DM
    Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
    Bonnekoh B; Schulz M; Franke I; Gollnick H
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients.
    Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M
    Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature.
    Gitelson E; Al-Saleem T; Millenson M; Lessin S; Smith MR
    Leuk Lymphoma; 2006 Sep; 47(9):1902-7. PubMed ID: 17065004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC; Siakantaris MP; Kalpadakis C; Dimopoulou MN; Vassilakopoulos TP; Kontopidou FN; Antoniou C; Korkolopoulou P; Panayiotidis P; Pangalis GA
    Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
    Abasq C; Duval-Modeste AB; Courville P; Joly P
    Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.